Extramedullary disease in multiple myeloma – controversies and future directions
Open Access
- 13 April 2019
- journal article
- review article
- Published by Elsevier BV in Blood Reviews
- Vol. 36, 32-39
- https://doi.org/10.1016/j.blre.2019.04.002
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health of the Czech Republic (AZV 17-29343A)
This publication has 66 references indexed in Scilit:
- Extramedullary involvement in multiple myelomaHaematologica, 2012
- Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling dataHaematologica, 2012
- Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsHaematologica, 2012
- Non-coding RNAs in human diseaseNature Reviews Genetics, 2011
- Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patientsCancer, 2011
- Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myelomaEuropean Journal of Haematology, 2011
- Characterization of extracellular circulating microRNANucleic Acids Research, 2011
- Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patientsAnnals Of Oncology, 2009
- MicroRNAs regulate critical genes associated with multiple myeloma pathogenesisProceedings of the National Academy of Sciences, 2008
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006